| 名称 | 获配股数 | 占全球发售 | 占上市后总股本 | 锁定期 |
|---|---|---|---|---|
| Aranda Investments Pte. Ltd. | 0 | 3.75% | — | 6个月 |
| Boyu Capital Opportunities Master Fund | 0 | 2.50% | — | 6个月 |
| Double Joy Ventures Limited | 0 | 2.50% | — | 6个月 |
| Hillhouse Funds | 0 | 3.75% | — | 6个月 |
| Hudson Bay Master Fund LTD | 0 | 1.25% | — | 6个月 |
| Invesco Advisers, Inc. | 0 | 10.00% | — | 6个月 |
| Janchor Partners Pan-Asian Master Fund | 0 | 1.25% | — | 6个月 |
| Lake Bleu Prime Healthcare Master Fund Limited | 0 | 2.50% | — | 6个月 |
| LAV Fund VI | 0 | 2.50% | — | 6个月 |
| Octagon Investments Master Fund LP | 0 | 1.25% | — | 6个月 |
| Sage Partners Master Fund | 0 | 1.25% | — | 6个月 |
| Springhill Master Fund Limited | 0 | 1.25% | — | 6个月 |
| UBS Asset Management (Singapore) Ltd. | 0 | 10.00% | — | 6个月 |
| Yi Fang Da Sirius Inv. Limited | 0 | 1.25% | — | 6个月 |
| 佳曦控股有限公司 | 0 | 2.50% | — | 6个月 |
本页展示 康诺亚生物医药科技有限公司 - B(02162)的打新中签分析:一手中签率、甲乙组中签分布、超额认购倍数、暗盘与首日表现。数据来自港交所配发结果公告。中签率的计算方式与回拨规则见港股中签率怎么算。

